Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189905 | 0.80 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPTPTGS1CHRM1 | |
| SCHEMBL28651642 | 0.78 | SLC1A3 (0.36) | ALDH1A1TSHRMAPTPTGS1HMGCR | |
| SCHEMBL9021784 | 0.77 | HSPD1 (0.36) | ALDH1A1TSHRRECQLCHRM1ADRA1A | |
| SCHEMBL12891264 | 0.76 | CA2 (0.41) | ALDH1A1TSHRMAPTPTGS1HMGCR | |
| SCHEMBL2631146 | 0.76 | CA2 (0.41) | ALDH1A1TSHRMAPTPTGS1HMGCR | |
| SCHEMBL667279 | 0.76 | OR51E2 (0.39) | ALDH1A1TSHRMAPTPTGS1HMGCR | |
| SCHEMBL276534 | 0.76 | CA2 (0.41) | ALDH1A1TSHRMAPTPTGS1HMGCR | |
| SCHEMBL13316605 | 0.76 | OR51E2 (0.39) | ALDH1A1TSHRMAPTPTGS1HMGCR | |
| SCHEMBL9107333 | 0.75 | HSPD1 (0.39) | ALDH1A1TSHRMAPTRECQLCA2 | |
| SCHEMBL8979255 | 0.74 | ALDH1A1 (0.32) | ALDH1A1TSHRMAPTPTGS1HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| US-10759822-B2 | Brain-targeting prodrug for AMPA receptor synergist, and pharmaceutical applications thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2020-09-01 | — | — | US | disclosed |
| CN-107286114-B | Brain-targeted prodrug of AMPA receptor synergist and medical application thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2020-08-18 | — | — | CN | disclosed |
| EP-3609870-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| CN-110357889-A | Protein degradation target compound, its antitumor application thereof, wherein mesosome and intermediate application | 上海科技大学 | 2019-10-22 | — | — | CN | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5506262-A | ANTICHOLESTEROL AGENTS, FUNGICIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1994001104-A1 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-5258401-A | Fused ring oxygen compounds, anticholesterol | MERCK & CO., INC. (US) | 1993-11-02 | — | — | US | disclosed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | ALDH1A1 1319/4885TSHR 2123/4885MAPT 3709/4885 |
| US-10759822-B2 | Brain-targeting prodrug for AMPA receptor synergist, and pharmaceutical applications thereof | GRM3, GRM1, GRM2 | ALDH1A1 933/4885TSHR 664/4885MAPT 428/4885 |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | ALDH1A1 4774/4885TSHR 2394/4885MAPT 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.